News | May 13, 2009

Cancer Biotherapy Market Could Reach $60B in 10 Years

May 13, 2009 - The biotherapies for cancer treatment may become a $60 billion market in 10 years, doubling in the next five years, according to a new report by Kalorama Information, “World Market for Cancer Therapeutics and Biotherapeutics, 3rd Edition.”

The report found that the biotherapy segment has recorded a 34.1 percent annual growth rate since 2004 and is forecast to nearly double by 2013.

With sales of $24.5 billion in 2008, biologics currently represents about half of the total cancer treatment market, but Kalorama expects its market share to increase to 60 percent by 2013.

“The future looks bright for biological cancer treatments,” said Melissa Elder, an analyst for Kalorama. “With many highly unpleasant and often dangerous side effects from traditional cancer treatments, the potential for targeted biologic therapies that help the body target malignant tumors while leaving healthy tissue intact offers hope to millions of suffering cancer patients.”

Several factors continue to fuel double-digit growth in biotherapeutics, including their success as a safer, more effective cancer therapy, the rising incidence of cancer and the increased cost for newly approved therapies in the biological area.

As the benefits of biologic products continue to be recognized, competition will likely intensify. Existing products will continue to lead the segment, the report stated, though innovative new products will display healthy growth and create new competition. The leading competitors in this market are limited to a handful of marketers, including Roche, Novartis, Bristol-Myers Squibb and Pfizer.

Biotherapeutics includes monoclonal antibodies, interleukins/interferons and kinases and other biotherapies. Monoclonal antibodies represent the lion’s share of this market, but the highest growth has been and will continue to be in the kinases and other biotherapy segments where several new approvals have contributed to phenomenal annual growth.

Source: www.healthcarefinancenews.com

Related Content

Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Lung Decision Precision
News | Lung Cancer | June 04, 2018
For smokers and former smokers, the threat of lung cancer always lurks in the shadows.
Metal artifact reduction led to a 20 percent increase in the planning target volume (PTV) in this prostate cancer case from Henry Ford Health System. The volume of the healthy bladder tissue to be spared was also reduced by 4 percent.

Metal artifact reduction led to a 20 percent increase in the planning target volume (PTV) in this prostate cancer case from Henry Ford Health System. The volume of the healthy bladder tissue to be spared was also reduced by 4 percent.

Feature | Computed Tomography (CT) | May 03, 2018 | By Jeff Zagoudis
Computed tomography (CT) has long been the standard of care for imaging to plan radiation therapy (RT) treatments. 
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

Feature | Proton Therapy | March 06, 2018 | By Jeff Zagoudis
Proton therapy has experienced major growth in the last decade, but that growth seems to have slowed slightly in recent...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.

This PET/CT shows metastasis of tumors, taken with the Philips TruFlight Select.

Feature | Radiation Oncology | January 31, 2018 | By Emily Clemons
Technological and scientific advances in radiation oncology are allowing practitioners to put patients first in...
Videos | Radiation Therapy | November 15, 2017
Chris Toth, president, global commercial and field operations for Varian, takes a tour of Varian’s new product introd
Overlay Init